Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2025-09-17 Sale | 2025-09-19 7:12 pm | Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO | 6,000 | $19.29 | $115,723 | 921,892 (Indirect) | View |
| 2025-09-08 Sale | 2025-09-10 8:12 pm | Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER | 6,667 | $20.24 | $134,957 | 283,308 (Indirect) | View |
| 2025-08-27 Sale | 2025-08-29 5:03 pm | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,250 | $20.63 | $67,039 | 131,306 (Direct) | View |
| 2025-08-20 Sale(A) | 2025-08-21 6:48 pm | Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO | 1,517 | $20 | $30,343 | 927,892 (Indirect) | View |
| 2025-08-19 Sale | 2025-08-21 6:46 pm | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 12,500 | $19.86 | $248,217 | 940,188 (Indirect) | View |
| 2025-08-18 Sale | 2025-08-20 4:36 pm | Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO | 10,983 | $20.02 | $219,906 | 929,409 (Indirect) | View |
| 2025-08-07 Sale | 2025-08-11 6:51 pm | Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER | 6,667 | $18.24 | $121,616 | 289,975 (Indirect) | View |
| 2025-07-28 Sale | 2025-07-30 5:57 pm | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,250 | $20.46 | $66,504 | 134,556 (Direct) | View |
| 2025-07-21 Sale | 2025-07-23 6:52 pm | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 12,500 | $22.29 | $278,646 | 952,688 (Indirect) | View |
| 2025-07-17 Sale | 2025-07-21 7:21 pm | Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO | 12,500 | $22.52 | $281,518 | 940,392 (Indirect) | View |
| 2025-07-10 Sale | 2025-07-14 5:07 pm | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 1,000 | $22.66 | $22,655 | 137,806 (Direct) | View |
| 2025-07-07 Sale | 2025-07-09 7:29 pm | Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER | 6,667 | $19.79 | $131,951 | 296,642 (Indirect) | View |
| 2025-06-27 Sale | 2025-07-01 4:42 pm | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,250 | $20.91 | $67,956 | 138,806 (Direct) | View |
| 2025-06-20 Sale | 2025-06-24 5:36 pm | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 12,500 | $21.4 | $267,458 | 965,188 (Indirect) | View |
| 2025-06-17 Sale | 2025-06-18 6:22 pm | Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO | 12,500 | $22.18 | $277,292 | 952,892 (Indirect) | View |
| 2025-06-13 Sale | 2025-06-17 4:24 pm | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,000 | $22.55 | $67,655 | 142,056 (Direct) | View |
| 2025-06-09 Sale | 2025-06-11 6:25 pm | Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER | 6,667 | $20.34 | $135,574 | 303,309 (Indirect) | View |
| 2025-06-03 Sale | 2025-06-05 4:55 pm | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 7,500 | $20.03 | $150,220 | 977,688 (Indirect) | View |
| 2025-06-03 Sale | 2025-06-05 4:53 pm | Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO | 7,500 | $20.05 | $150,352 | 965,392 (Indirect) | View |
| 2025-05-27 Sale | 2025-05-29 5:38 pm | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,250 | $16.18 | $52,593 | 145,056 (Direct) | View |
| 2025-05-19 Sale | 2025-05-21 6:31 pm | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 5,000 | $16.31 | $81,534 | 985,188 (Indirect) | View |
| 2025-05-19 Sale | 2025-05-21 6:29 pm | Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO | 5,000 | $16.49 | $82,453 | 972,892 (Indirect) | View |
| 2025-05-07 Sale | 2025-05-09 6:48 pm | Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER | 6,667 | $18.39 | $122,579 | 309,976 (Indirect) | View |
| 2025-05-01 Sale | 2025-05-05 6:43 pm | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 7,500 | $20.05 | $150,391 | 990,188 (Indirect) | View |
| 2025-05-01 Sale | 2025-05-05 6:42 pm | Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO | 7,500 | $20.06 | $150,415 | 977,892 (Indirect) | View |
| 2025-04-28 Sale | 2025-04-30 6:59 pm | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,250 | $18.69 | $60,738 | 148,306 (Direct) | View |
| 2025-04-21 Sale | 2025-04-23 5:09 pm | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 5,000 | $16.07 | $80,366 | 997,688 (Indirect) | View |
| 2025-04-17 Sale | 2025-04-21 5:55 pm | Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO | 5,000 | $16.42 | $82,096 | 985,392 (Indirect) | View |
| 2025-04-07 Sale | 2025-04-09 4:25 pm | Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER | 6,667 | $18.04 | $120,269 | 316,643 (Indirect) | View |
| 2025-03-27 Sale | 2025-03-31 7:37 pm | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,250 | $21.33 | $69,321 | 151,556 (Direct) | View |
| 2025-03-24 Sale | 2025-03-26 7:37 pm | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 1,000 | $22.5 | $22,505 | 154,806 (Direct) | View |
| 2025-03-19 Sale | 2025-03-21 5:49 pm | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 12,500 | $20.61 | $257,575 | 1,002,688 (Indirect) | View |
| 2025-03-17 Sale | 2025-03-19 5:42 pm | Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO | 12,500 | $20.83 | $260,320 | 990,392 (Indirect) | View |
| 2025-03-07 Sale | 2025-03-11 5:18 pm | Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER | 6,667 | $21.44 | $142,936 | 323,310 (Indirect) | View |
| 2025-02-27 Sale | 2025-03-03 8:07 pm | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,250 | $20.41 | $66,327 | 155,806 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2025-08-27 Exercise | 2025-08-29 5:03 pm | N/A 2031-08-02 | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,250 | $0 | 131,306 (Direct) | View |
| 2025-08-27 Exercise | 2025-08-29 5:03 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,250 | $2.48 | 131,306 (Direct) | View |
| 2025-07-28 Exercise | 2025-07-30 5:57 pm | N/A 2031-08-02 | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,250 | $0 | 134,556 (Direct) | View |
| 2025-07-28 Exercise | 2025-07-30 5:57 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,250 | $2.48 | 134,556 (Direct) | View |
| 2025-07-10 Exercise | 2025-07-14 5:07 pm | N/A 2031-08-02 | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 1,000 | $0 | 137,806 (Direct) | View |
| 2025-07-10 Exercise | 2025-07-14 5:07 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 1,000 | $2.48 | 137,806 (Direct) | View |
| 2025-06-27 Exercise | 2025-07-01 4:42 pm | N/A 2031-08-02 | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,250 | $0 | 138,806 (Direct) | View |
| 2025-06-27 Exercise | 2025-07-01 4:42 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,250 | $2.48 | 138,806 (Direct) | View |
| 2025-06-13 Exercise | 2025-06-17 4:24 pm | N/A 2031-08-02 | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,000 | $0 | 142,056 (Direct) | View |
| 2025-06-13 Exercise | 2025-06-17 4:24 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,000 | $2.48 | 142,056 (Direct) | View |
| 2025-05-27 Exercise | 2025-05-29 5:38 pm | N/A 2031-08-02 | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,250 | $0 | 145,056 (Direct) | View |
| 2025-05-27 Exercise | 2025-05-29 5:38 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,250 | $2.48 | 145,056 (Direct) | View |
| 2025-04-28 Exercise | 2025-04-30 6:59 pm | N/A 2031-08-02 | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,250 | $0 | 148,306 (Direct) | View |
| 2025-04-28 Exercise | 2025-04-30 6:59 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,250 | $2.48 | 148,306 (Direct) | View |
| 2025-03-27 Exercise | 2025-03-31 7:37 pm | N/A 2031-08-02 | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,250 | $0 | 151,556 (Direct) | View |
| 2025-03-27 Exercise | 2025-03-31 7:37 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,250 | $2.48 | 151,556 (Direct) | View |
| 2025-03-24 Exercise | 2025-03-26 7:37 pm | N/A 2031-08-02 | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 1,000 | $0 | 154,806 (Direct) | View |
| 2025-03-24 Exercise | 2025-03-26 7:37 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 1,000 | $2.48 | 154,806 (Direct) | View |
| 2025-03-04 Exercise | 2025-03-06 6:02 pm | N/A 2031-08-02 | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 10,000 | $0 | 155,806 (Direct) | View |
| 2025-03-04 Exercise | 2025-03-06 6:02 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 10,000 | $2.48 | 155,806 (Direct) | View |
| 2025-02-27 Exercise | 2025-03-03 8:07 pm | N/A 2031-08-02 | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,250 | $0 | 155,806 (Direct) | View |
| 2025-02-27 Exercise | 2025-03-03 8:07 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,250 | $2.48 | 155,806 (Direct) | View |
| 2025-02-06 Option Award | 2025-02-10 5:40 pm | N/A 2035-02-06 | Enliven Therapeutics Inc. | ELVN | Phillips Andrew John Director | 20,491 | $0 | 20,491 (Direct) | View |
| 2025-02-06 Option Award | 2025-02-10 5:39 pm | N/A 2035-02-06 | Enliven Therapeutics Inc. | ELVN | Kunkel Lori Anne Director | 15,368 | $0 | 15,368 (Direct) | View |
| 2025-02-06 Option Award | 2025-02-10 5:38 pm | N/A 2035-02-06 | Enliven Therapeutics Inc. | ELVN | Heyman Richard A. Director | 23,014 | $0 | 23,014 (Direct) | View |
| 2025-02-06 Option Award | 2025-02-10 5:36 pm | N/A 2035-02-06 | Enliven Therapeutics Inc. | ELVN | Gupta Rishi Director 10% Owner | 20,491 | $0 | 20,491 (Direct) | View |